Liraglutide: difference between revisions
Diff·revision 6 → 7·15:01, 6 Oct 2024
Difference between revision 6 and revision 7 of Liraglutide. 5 lines changed; the page grew by 135 bytes.
| Revision 6 — 07:15, 22 Sep 2024 CiteBot (talk) bot: repair redlinked category 3,104 bytes +611 | Revision 7 — 15:01, 6 Oct 2024 CiteBot (talk) bot: add drug-class category 3,239 bytes +135 | ||
|---|---|---|---|
| 5 | | Route = Subcutaneous, daily | 5 | | Route = Subcutaneous, daily |
| 6 | | First approval = 2009 (type 2 diabetes) | 6 | | First approval = 2009 (type 2 diabetes) |
| + | 7 | <!-- Identifiers --> | |
| + | 8 | | CAS Number = 204656-20-2 | |
| + | 9 | | Molar mass = 3,751.20 g·mol⁻¹ | |
| + | 10 | | Residues = 31 | |
| 7 | }} | 11 | }} |
| 8 | 12 | ||
| ⋮ | ⋮ | ||
| 29 | [[Category:GLP-1 receptor agonists]] | 33 | [[Category:GLP-1 receptor agonists]] |
| 30 | [[Category:Peptide drugs]] | 34 | [[Category:Peptide drugs]] |
| + | 35 | [[Category:Pharmacokinetics]] | |
| 31 | 36 |